Abstract
Objective The objective of this study was to quantify longitudinal changes in Unified Huntington’s Disease Rating Scale (UHDRS) clinical scores and evaluate their susceptibility to placebo response, improving our understanding of disease progression and the ability to optimize clinical trials in Huntington’s disease.
Methods We utilized data from the Enroll-HD and GENERATION HD1 placebo arm cohorts to model the natural history of the disease and placebo response for functional, motor and cognitive clinical scores. Baseline patient characteristics available in both cohorts were analyzed as potential predictors of progression rate.
Results We identified distinct trajectories for each clinical measurement throughout the course of the disease, with baseline characteristics serving as strong predictors of progression rate. Interestingly, we observed a weak correlation between progression rates among different endpoints, highlighting the need for careful selection of endpoints, as they may not have the same relevance for different patient populations.
To quantify placebo response, we compared disease progression in the largest Huntington’s clinical trial to date (GENERATION HD1 placebo arm) to the Enroll-HD cohort. We found a strong initial improvement in motor and cognitive scores in GENERATION HD1, which remained constant during the dosing period of the trial. We show that this initial improvement in motor and cognitive scores can be quantified, enabling the simulation of changes in endpoints in a placebo arm for distinct subpopulations.
Interpretation Our model successfully captures essential aspects of disease progression and placebo response in Huntington’s disease, providing valuable guidance for the design and analysis of upcoming clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Supported by F. Hoffmann-La Roche.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Enroll-HD periodic data set 5 (PDS5) is accessible through the Enroll-HD website (enroll-hd.org/). For clinical trial studies, qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing, this request platform is Vivli. https://vivli.org/ourmember/roche/. For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://go.roche.com/data_sharing. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient re-identification.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Enroll-HD periodic data set 5 (PDS5) is accessible through the Enroll-HD website (enroll-hd.org/). For clinical trial studies, qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing, this request platform is Vivli. https://vivli.org/ourmember/roche/. For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://go.roche.com/data_sharing. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient re-identification.
